エーザイのアルツハイマー病／認知症領域の開発品に関する最新データをアルツハイマー病協会国際会議 2021（AAIC2021）にて発表 Eisai Jul 21, 2021 09:00 JST Read More
Eisai Launchs Bile Acid Transporter Inhibitor Goofice in Thailand Eisai Jul 19, 2021 08:03 HKT/SGT Read More
南オーストラリア州首相、150万ドルのワクチン・免疫生物学の最先端研究所を開所 アジア太平洋地域における臨床試験に対応 Agilex Biolabs Jul 15, 2021 17:05 JST Read More
Adlai Nortye Raises $100 Million in Series D Financing, Co-led by SDIC Fund Management and Tigermed, participated by Legend Star, WuXi Biologics Healthcare Ventures Adlai Nortye Jul 15, 2021 11:28 JST Read More
南オーストラリア州首相、150万ドルのワクチン・免疫生物学の最先端研究所を開所 アジア太平洋地域における臨床試験に対応 Agilex Biolabs Jul 15, 2021 07:00 JST Read More
NEC's artificial intelligence (AI) supports doctors to determine if colorectal lesions are potentially neoplastic NEC Corporation Jul 14, 2021 17:15 HKT/SGT Read More
Avance Clinical Congratulates Client Tetherex Pharmaceuticals on Initiation of Dosing in a Phase 1 Clinical Study Using a Novel Single-Cycle Adenovirus Vaccine Strategy in Australia Avance Clinical Jul 09, 2021 21:00 JST Read More
バイオジェンとエーザイ、ADUHELM(TM)の添付文書について臨床試験の対象患者様層を明確化するための添付文書の更新を米国FDAが承認 Eisai Jul 09, 2021 09:00 JST Read More
Eisai Launches In-house Developed Anti-insomnia Drug Dayvigo (Lemborexant) In Hong Kong Eisai Jul 01, 2021 10:43 HKT/SGT Read More
Eisai and Biogen Inc. Announce U.S. FDA Grants Breakthough Therapy Designation for Lecanemab (BAN2401) Eisai Jun 24, 2021 11:00 HKT/SGT Read More
エーザイ、抗がん剤「タズベリク(R)錠200mg」について日本においてEZH2遺伝子変異陽性の濾胞性リンパ腫に係る効能効果で製造販売承認を取得 Eisai Jun 24, 2021 10:00 JST Read More
Anticancer Agent "Tazverik Tablets 200mg" (Tazemetostat Hydrobromide) Approved In Japan For EZH2 Gene Mutation-positive Follicular Lymphoma Eisai Jun 23, 2021 14:20 HKT/SGT Read More
Fujitsu Japan Embarks on Joint Research for COVID-19 Therapies Using World's Fastest Supercomputer with Researchers of RCAST, The University of Tokyo Fujitsu Ltd Jun 22, 2021 09:30 HKT/SGT Read More
